The diverse CB₁ and CB₂ receptor pharmacology of three plant cannabinoids: Δ⁹‐tetrahydrocannabinol, cannabidiol and Δ⁹‐tetrahydrocannabivarin

British Journal of Pharmacology - Tập 153 Số 2 - Trang 199-215 - 2008

Roger G. Pertwee¹

¹School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

Tóm tắt

Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (−)‐trans‐Δ⁹‐tetrahydrocannabinol (Δ⁹‐THC), (−)‐cannabidiol (CBD) and (−)‐trans‐Δ⁹‐tetrahydrocannabivarin (Δ⁹‐THCV), interact with cannabinoid CB₁ and CB₂ receptors. Δ⁹‐THC, the main psychotropic constituent of cannabis, is a CB₁ and CB₂ receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. CBD displays unexpectedly high potency as an antagonist of CB₁/CB₂ receptor agonists in CB₁‐ and CB₂‐expressing cells or tissues, the manner with which it interacts with CB₂ receptors providing a possible explanation for its ability to inhibit evoked immune cell migration. Δ⁹‐THCV behaves as a potent CB₂ receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB₁‐expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent. Δ⁹‐THCV also interacts with CB₁ receptors when administered in vivo, behaving either as a CB₁ antagonist or, at higher doses, as a CB₁ receptor agonist. Brief mention is also made in this review, first of the production by Δ⁹‐THC of pharmacodynamic tolerance, second of current knowledge about the extent to which Δ⁹‐THC, CBD and Δ⁹‐THCV interact with pharmacological targets other than CB₁ or CB₂ receptors, and third of actual and potential therapeutic applications for each of these cannabinoids.

British Journal of Pharmacology (2008) 153, 199–215; doi:10.1038/sj.bjp.0707442; published online 10 September 2007

Từ khóa

Tài liệu tham khảo

10.1074/jbc.M608900200

10.1016/j.pain.2006.04.001

10.1038/sj.bjp.0704829

10.1074/jbc.271.17.9902

10.1111/j.1460-9568.2006.04684.x

10.1007/s00213-002-1144-9

10.1002/syn.1075

Bifulco M, 2007, Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review), Oncol Rep, 17, 813

10.1038/sj.bjp.0704327

10.1096/fj.06-6638fje

10.1016/j.ejphar.2004.10.043

10.1016/j.ejphar.2006.10.038

10.1046/j.1471-4159.1999.0732447.x

10.1124/mol.60.1.155

10.1002/bms.1200150708

10.1021/jm950934b

Cabral GA, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 385

10.1016/j.brainres.2006.06.001

10.1158/0008-5472.CAN-06-0169

10.1073/pnas.0511232103

Cawthorne MA, 2007, Symposium on the Cannabinoids

10.1016/S0028-3908(98)00208-1

10.1208/aapsj080113

10.1111/j.1528-1157.1979.tb04816.x

10.1016/S0006-8993(01)02825-6

10.1016/0091-3057(82)90418-X

10.1016/j.pbb.2004.10.019

10.1016/j.ejphar.2004.02.018

10.1097/00008877-200402000-00001

DennisI WhalleyB StephensG(2007).Effects of cannabinoids on [35S]GTPγS binding in specific regions of the mouse brain. Poster P041 at theJoint Focused Meeting/3rd European Workshop on Cannabinoid Research University of Nottingham UK 20 and 21 April 2007. Focused Meeting of the British Pharmacological Society.

10.1126/science.1470919

Dewey WL, 1986, Cannabinoid pharmacology, Pharmacol Rev, 38, 151

10.1046/j.1471-4159.2000.0752434.x

Di Marzo V, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 147

10.1016/j.neuropharm.2005.11.008

Felder CC, 1995, Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol Pharmacol, 48, 443

10.1007/BF01065669

10.1517/13543784.14.6.695

10.1016/j.pbb.2005.01.032

Gauson LA, 2007, Symposium on the Cannabinoids

10.1038/228134a0

10.1016/j.brainres.2005.11.035

10.1111/j.1749-6632.1999.tb09356.x

10.1038/nrc1188

Guzmán M, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 627

10.1038/sj.bjc.6603236

10.1016/S0028-3908(02)00157-0

10.1111/j.1460-9568.2007.05476.x

10.1016/j.ejphar.2006.07.024

10.1124/mol.105.019174

10.1073/pnas.87.5.1932

10.1016/j.yexcr.2006.03.009

10.1159/000136462

10.1124/pr.54.2.161

10.1016/S0968-0896(99)00219-9

Iwamura H, 2001, In vitro and in vivo pharmacological characterization of JTE‐907, a novel selective ligand for cannabinoid CB2 receptor, J Pharmacol Exp Ther, 296, 420

10.1016/S0016-5085(03)00892-8

Izzo AA, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 573

10.1038/sj.bjp.0704293

10.1097/00008877-200509000-00009

10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P

10.1016/j.pbb.2005.01.026

10.1007/s00210-006-0033-x

10.1016/j.neuropharm.2003.11.005

10.1016/j.ejphar.2006.05.025

10.1152/ajpgi.00407.2005

10.1093/jb/mvi021

10.1111/j.1471-4159.2006.03873.x

10.1016/j.cub.2005.07.005

10.1093/bja/aei098

10.1124/jpet.104.077974

10.1172/JCI107431

Lichtman AH, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 691

10.1016/S0304-3959(03)00242-2

10.1016/j.physbeh.2006.04.014

10.1124/jpet.105.093500

Ma Y‐L, 2006, The phytocannabinoid Δ9‐tetrahydrocannabivarin modulates synaptic transmission at central inhibitory synapses, Proc Br Pharmacol Soc

10.1038/sj.bjp.0701915

MacLennan SJ, 1998, Symposium on the Cannabinoids

10.1016/j.tins.2006.01.008

10.1517/14728222.11.3.403

10.1038/sj.bjp.0704220

10.1111/j.1471-4159.2005.03380.x

10.1038/nm1561

10.1016/0091-3057(91)90349-7

10.1172/JCI200419465

10.1016/j.tem.2006.11.006

10.1038/346561a0

10.1007/s11060-004-5950-2

McHugh D, 2005, Symposium on the Cannabinoids

10.1182/blood-2002-01-0098

10.1038/sj.bjp.0706415

10.1016/0006-2952(95)00109-D

10.1038/sj.bjp.0707261

10.1038/232579a0

10.1016/j.pain.2006.06.016

10.1016/S0197-0186(01)00076-6

10.1016/j.neuron.2006.07.006

10.1006/bbrc.2002.6635

10.1038/365061a0

10.1016/j.pbb.2006.05.018

10.1016/j.bbrc.2005.09.121

10.1016/j.pharmthera.2005.09.009

10.1007/3-7643-7358-X_10

10.1007/s00213-002-1329-2

10.1124/jpet.106.101287

10.1016/0163-7258(88)90106-4

10.1038/sj.bjp.0704327

10.2174/0929867306666220401124036

10.1007/s10681-004-4756-9

Pertwee RG, 2004, Cannabinoids, 32

Pertwee RG, 2004, Novel pharmacological targets for cannabinoids, Curr Neuropharmacol, 2, 9, 10.2174/1570159043476927

Pertwee RG, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 1

10.1208/aapsj070364

10.1007/3-7643-7358-X_3

10.1038/sj.bjp.0706406

10.1007/s12035-007-0005-2

Pertwee RG, 2007, GPR55: a new member of the cannabinoid receptor clan?, Br J Pharmacol

10.1054/plef.2001.0341

Pertwee RG, 2002, Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens, Eur J Pharmacol, 456, 99, 10.1016/S0014-2999(02)02624-9

Pertwee RG, 2007, Signs of cannabinoid CB2 receptor activation by tetrahydrocannabivarin, cannabigerol and cannabidiol, IACM Fourth Conference on Cannabinoids in Medicine

Pertwee RG, 2007, The Cannabinoid Receptors

10.1038/sj.bjp.0707124

10.1016/S0024-3205(98)00238-0

10.1016/j.neuropharm.2005.11.023

10.1016/S0006-8993(02)03055-X

10.1038/sj.bjp.0707003

Rakhshan F, 2000, Carrier‐mediated uptake of the endogenous cannabinoid anandamide in RBL‐2H3 cells, J Pharmacol Exp Ther, 292, 960

10.1021/jm970126f

10.1016/0014-5793(94)00773-X

Robinson L, 2007, Phytocannabinoid induced anorexic behaviour in fasted and non‐fasted mice, IACM Fourth Conference on Cannabinoids in Medicine

Robson P, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 719

10.1016/S0028-3908(00)00135-0

10.1007/s11064-005-6978-1

Ryberg E, 2007, The orphan receptor GPR55 is a novel cannabinoid receptor, Br J Pharmacol, 10.1038/sj.bjp.0707460

10.1016/j.jneuroim.2004.10.003

10.1111/j.1365-2982.2006.00819.x

10.1158/0008-5472.CAN-04-3410

10.1007/s00213-006-0676-9

10.1124/mol.55.1.8

10.1111/j.1471-4159.2006.04346.x

10.1016/j.neuropharm.2005.11.008

10.1016/S0014-2999(01)00798-1

10.1523/JNEUROSCI.16-24-08057.1996

10.1615/CritRevNeurobiol.v15.i2.10

10.1124/jpet.102.035618

10.1073/pnas.93.9.3984

10.1097/01.mol.0000245257.17764.b2

10.1038/nature03389

10.1113/jphysiol.2005.091918

10.1006/bbrc.1995.2437

10.1007/3-540-26573-2_11

10.1089/jop.2006.22.160

10.1038/sj.bjp.0707133

10.1016/j.ejphar.2004.01.023

10.1038/sj.bjp.0706414

10.1097/01.ijg.0000212260.04488.60

10.1136/bjo.2003.032250

10.1002/j.1552-4604.1981.tb02625.x

10.1126/science.1115740

10.1152/ajpgi.00113.2003

10.1124/jpet.104.080739

Vaughan CW, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 367

10.1038/37371

10.1002/jnr.20821

10.1124/jpet.103.051920

10.1016/S0014-2999(01)01243-2

10.1523/JNEUROSCI.23-04-01398.2003

10.1038/sj.bjp.0705667

10.1248/cpb.38.2317

Weston S, 2006, Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity, Proc Br Pharmacol Soc

10.2174/092986707780363023

10.1038/sj.bjp.0706157

Wiley JL, 2001, Novel pyrazole cannabinoids: insights into CB1 receptor recognition and activation, J Pharmacol Exp Ther, 296, 1013

10.1016/j.ejphar.2005.01.006

10.1016/j.jdermsci.2006.10.009

10.1021/jm00241a012

10.1016/j.neuroscience.2005.06.009

10.1189/jlb.0307159

10.1016/j.cancergencyto.2006.06.014

10.1186/1471-2377-6-12

10.1046/j.1460-9568.2003.02704.x

10.1073/pnas.96.10.5780

10.1523/JNEUROSCI.22-11-04720.2002

Scholar Hub - Công cụ hỗ trợ trích dẫn và phân tích khoa học Việt Nam

Về chúng tôi

Scholar Hub là công cụ hỗ trợ trích dẫn và phân tích các bài báo, công bố khoa học Việt Nam. Công cụ trợ giúp người nghiên cứu, tạp chí, đơn vị nghiên cứu tra cứu, phân tích và thống kê dữ liệu nghiên cứu khoa học tại Việt Nam và quốc tế.
ScholarHub KHÔNG đăng thông tin tổng hợp, KHÔNG đăng lại nội dung từ các trang báo chí Việt Nam hoặc trang thông tin điện tử khác tại Việt Nam.